A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Name: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Published: 2022
License: Public Domain

Novartis Pharmaceuticals · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, aml, azacitidine, venetoclax, tp53, mdm2, siremadlin, hdm201, unfit aml, newly diagnosed unfit aml, presenting with high-risk clinical features, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Related documents